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Background: Parkinson’s disease (PD) patients are affected by hypokinetic dysarthria, 
characterized by hypophonia and dysprosody, which worsens with disease progression. 
Levodopa’s (l-dopa) effect on quality of speech is inconclusive; no data are currently 
available for late-stage PD (LSPD).
Objective: To assess the modifications of speech and voice in LSPD following an acute 
l-dopa challenge.
Method: LSPD patients [Schwab and England score <50/Hoehn and Yahr stage >3 
(MED ON)] performed several vocal tasks before and after an acute l-dopa challenge. 
The following was assessed: respiratory support for speech, voice quality, stability and 
variability, speech rate, and motor performance (MDS-UPDRS-III). All voice samples 
were recorded and analyzed by a speech and language therapist blinded to patients’ 
therapeutic condition using Praat 5.1 software.
results: 24/27 (14 men) LSPD patients succeeded in performing voice tasks. Median 
age and disease duration of patients were 79 [IQR: 71.5–81.7] and 14.5 [IQR: 11–15.7] 
years, respectively. In MED OFF, respiratory breath support and pitch break time of LSPD 
patients were worse than the normative values of non-parkinsonian. A correlation was 
found between disease duration and voice quality (R = 0.51; p = 0.013) and speech rate 
(R = −0.55; p = 0.008). l-Dopa significantly improved MDS-UPDRS-III score (20%), with 
no effect on speech as assessed by clinical rating scales and automated analysis.
conclusion: Speech is severely affected in LSPD. Although l-dopa had some effect on 
motor performance, including axial signs, speech and voice did not improve. The appli-
cability and efficacy of non-pharmacological treatment for speech impairment should be 
considered for speech disorder management in PD.
Keywords: Parkinson’s disease, late stage, levodopa, speech, voice
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inTrODUcTiOn
Parkinson’s disease (PD) patients are classically affected by 
hypokinetic dysarthria, characterized by hypophonia and dys-
prosody, that worsens with disease progression due to breathing, 
phonation, and articulation dysfunction (1–3). Speech disorders 
affect nearly 90% of PD patients and have a negative impact 
on functional communication, which in turn contributes to 
decreased quality of life (4, 5). Symptoms vary from a soft and 
breathy voice that lacks modulation in volume (monoloudness) 
and fundamental frequency (monopitch or monotone) resulting 
in flat speech melody (dysprosody), with pitch breaks, lack of 
rhythm and pace of speech, number of pauses, reduced stress, and 
imprecision in consonant articulation, to a voice that is neither 
audible nor intelligible (6–9).
The effect of levodopa (l-dopa) on the quality of speech is 
inconclusive given that it is also influenced by each patient’s 
speech profile. Some studies report on a slight improvement of 
intonation, vowel articulation, and speech intelligibility (10–13), 
while others show no significant effect (14, 15) as measured dur-
ing an acute l-dopa challenge. Nevertheless, speech is generally 
considered to be an “l-dopa-resistant” axial motor symptom of 
PD (16). Axial impairment is preponderant among PD patients 
in the latest disease stage (17), although no data are currently 
available on the effect of l-dopa on speech among late-stage PD 
(LSPD) patients. The purpose of this study was to assess the clini-
cal and active modifications of speech and voice after an acute 
l-dopa challenge in an LSPD population.
PaTienTs anD MeThODs
Design and recruitment
We performed a cross-sectional study in a consecutive sample 
of LSPD patients recruited during 12  months from the move-
ment disorders outpatient clinic of a tertiary university hospital 
(Hospital Santa Maria, Lisbon, Portugal). PD was defined accord-
ing to the UK Brain Bank criteria (18), whereas LSPD was defined 
as PD patients with either a Schwab and England score <50 
(MED ON) or a Hoehn and Yahr stage (HY) >3 (MED ON) (19). 
The Local Ethics Committee approved the study. All subjects gave 
written informed consent in accordance with the Declaration of 
Helsinki.
assessment of Patients
Late-stage PD patients were first assessed in the practically 
defined “MED OFF” condition and then 60–90 min after l-dopa 
intake in the best “MED ON” condition. For the l-dopa challenge, 
each patient took her/his usual morning l-dopa equivalent dose 
plus 50% (supramaximal dose = 150%). l-Dopa equivalent daily 
dose was calculated according to recognized standard conver-
sions (20). Details of the l-dopa challenge have been previously 
reported (19).
The following parameters were assessed during both MED 
OFF and MED ON: (a) motor performance by means of the 
MDS-UPDRS part III (21); (b) severity of dyskinesias using the 
Modified Abnormal Involuntary Movement Scale (mAIMS); 
(c) respiratory support for speech (time duration of vowel/a/
prolongation); (d) voice quality [fundamental frequency (F0)]; 
(e) voice stability (pitch break time and jitter); (f) voice variabil-
ity [SD of speaking F0 during sentences (Sentence F0SD)]; and 
(g) speech rate (syllables/s). Each participant had to perform 
several vocal tasks that consisted of the following: (i) sustained 
phonation of the vowel/a/at a comfortable pitch and loudness 
and (ii) repeating an 8-word, 14-syllable standard statement/
declarative sentence, “A Maria comprou-me um mapa do 
papel branco” [translation: Mary bought me a map of white 
paper]; and (iii) reading 5 words and 5 sentences. Tasks were 
selected from the European Portuguese version of the Frenchay 
Dysarthria Assessment version 2 (22). However, due to the low 
level of cooperation of LSPD patients, we adopted an 8-word 
(14 syllables) declarative sentence (syntactically simple) that in 
European Portuguese is expected to have a low level of voice 
variability compared to complex sentences or text reading, 
which are normally used for this task.
Patients were seated and instructed by a neurologist to sustain 
the vowel/a/at a comfortable pitch and loudness as long as they 
could. A demonstration was made by the clinician before the 
patient performed each vocal task. There were no time limits for 
each participant and he/she was asked to repeat the task if the 
examiner was not fully satisfied with patient’s performance.
All voice samples were recorded in a room in a home envi-
ronment using a tabletop unidirectional microphone (Fame, 
MS-1800S) attached to a preamplifier (M-Audio Fast Track Pro, 
preamp, USB) and a desktop computer running Audacity soft-
ware version 2.1.2 (Free software Foundation Europe, Hamburg, 
Germany).
Two separate perceptual files were completed using Audacity 
software version 2.1.2 with all the stimuli presented at the same 
sound pressure levels and with a 500 ms silence between single 
words and sentences.
MDS-UPDRS parts II and IV were used to assess the impact 
of motor symptoms on activities of daily life and l-dopa-induced 
motor complications, respectively. PD with dementia was diag-
nosed according MDS Task Force recommendations (23).
Data analysis
All voice samples were copied to a computer (down sampled to 
24 kHz, 16 bits, mono), edited into individual files and screened 
for extraneous noise using Audacity by a speech language thera-
pist with expertise in experimental phonetics and who was not 
involved in data gathering and was blind to the participants’ 
demographics and clinical status.
Acoustically, the waveform, spectrogram, pitch, intensity, 
and the formants of each sustained vowel were visually observed 
using the Praat 5.1 software (24) downloaded from http://www.
praat.org.
The vowel/a/mean and SD F0 (Hz), jitter (local, %) and har-
monic-to-noise-ratio (dB) were analyzed with a moving window 
with at least 1-s using voice report in the Praat software.
The following parameters were analyzed: (a) Respiratory sup-
port for speech. Duration (s) was measured as the total period 
between the onset and offset of each sustained vowel/a/and the 
breath(s) during speech in the sentence “A Maria comprou-me 
TaBle 1 | Values are presented as median [IQR, 25th–75th percentile] if no otherwise specified.
Patients data lsPD (n = 24) lsPD
Male (n = 14)
lsPD
Female (n = 10)
p-Value
Age (years) 79 [71.5–81.7] 77.5 [70.7–81.2] 79 [73.5–85] ns
Age at disease onset (years) 64.5 [54.5–69.5] 62.5 [55–67] 65 [51.5–71.5] ns
Disease duration 14.5 [11–15.7] 13.5 [8.7–17] 15 [11.7–17.2] ns
Education (years) 4 [4–11] 4 [4–12] 5 [4–10.5] ns
S&E (ON/OFF) 40/35 [40–40.7/22.5–40] 40/30 [40–40/40–40] 40/30 [27–50/17.5–50] ns
HY (ON/OFF) 4 [2–4]/4 [2–4.75] 3 [2–4]/3 [2–4] 4 [4–5]/4 [4–5] ns
PDD [n (%)] 14 (58%) 10 (71%) 4 (40%) ns
MMSE 22.5 [21.2–25] 22.5 [22–24.2] 22.5 [16–27.2] ns
MMSE (demented/non-demented) 22 [17–23.7]/25 [23–26.7] 22 [21.7–24.2]/23 [22.2–25.2] 17 [13–19.5]/27 [25–28.5]
LEDD (mg) 1,037 [902–1,272] 1,100 [990–1,303] 905 [742–1,257] ns
MDS-UPDRS-II 31 [27–38] 32 [29.2–38.5] 30 [20.5–38] ns
MDS-UPDRS-III (MED ON/MED OFF) 50 [40–54]/64 [52–77] 50 [42.5–55.2]/61 [53–76] 50 [37.5–62.5]/64 [48–79.5] ns
Axial sign (MED ON/MED OFF) 8 [6–13]/10 [7–13] 8 [6–13]/10 [7–13.2] 8 [6.5–12]/10 [7–13.5] ns
MDS-UPDRS-IV 4 [2–9.5] 5 [2–8.5] 4 [0–11.2] ns
LEDD, l-dopa equivalent daily dose; PDD, Parkinson’s disease with dementia; MMSE, mini mental state examination; S&E, Schwab and England score; HY, Hoehn and Yahr stage; 
ns, non-significant; LSPD, late-stage PD.
p-Value is the results for male versus female scores’ comparison.
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um mapa de papel branco”; (b) Voice (pitch) quality. The average 
F0 (Hz) was analyzed in all vowels in the two moments. Vowel/a/
was perceptually analyzed by a speech language therapist for pitch 
and loudness level along the production (mainly high or low); (c) 
Voice (pitch) stability. The assigned acoustic parameters were as 
follows: Pitch breaks (no pitch contour) time (seconds) and jitter 
(local, %). Vowel/a/was perceptually analyzed by considering the 
pitch and loudness stability (maintained, increased, decreased or 
uncontrolled); (d) Voice variability. Variability was considered as 
speech F0SD in hertz in the sentence (Sentence F0SD). At baseline 
(MED OFF) the F0SD (Hz) was also analyzed; and (e) Speech rate. 
Speech rate of the sentence “A Maria comprou-me um mapa de 
papel branco” [Mary bought me a map of white paper], total 
number of orthographic syllables divided by total time duration 
(including pauses).
statistical analysis
Descriptive statistics of demographic, clinical, and therapeutic 
data were provided for continuous (median and interquartile 
range [IQR, 25th–75th percentile]) and categorical (count and 
percentage) variables.
Voice and speech characteristics at baseline (MED OFF) of 
LSPD patients, considering men and women separately, were 
compared to the available normal values of healthy age-matched 
subjects, although no statistical analyses were performed.
The acute effect of l-dopa on voice and speech was calculated 
by comparing the median duration of the vowel/a/, average F0, 
pitch breaks duration, jitter, SF0SD, and speech rate between 
MED OFF versus MED ON conditions. Comparisons were made 
using the Wilcoxon’s signed-rank test.
Spearman’s rank correlation coefficient was used to assess 
the association between: (a) respiratory support for speech, 
voice quality, voice stability, voice variability, speech and disease 
duration, and motor impairment (MDS-UPDRS-III)/axial motor 
impairment (sum of items 3.1, 3.10–3.12 of the MDS-UPDRS-III); 
(b) speech rate and freezing (item 3.11 of the MDS-UPDRS-III).
Two group comparisons (women versus men) were performed 
using the Mann–Whitney U-test.
Reliability of Analyses
To evaluate test–retest reliability of acoustic measurements the 
sustained vowel/a/for an average F0 was run twice. A satisfying 
test–retest reliability was found (R = 0.722, p < 0.001, Pearson 
test), only one single-speech-task cycle was performed for the 
definite acoustic measurements.
A p value < 0.05 was considered significant. The analysis of 
the results was carried out by means of SPSS 21.0 (SPSS, Chicago, 
IL, USA).
resUlTs
clinical Data
Twenty-seven LSPD patients were recruited for speech and voice 
analyses. Three were excluded due to their inability to perform 
the required tasks (one anarthric patient and two due to severe 
dementia). Demographic and clinical data of the 24 LSPD patients 
are detailed in Table 1.
There were no differences in demographic or clinical variables 
between men and women (Table  1). Indeed, they presented 
similar MDS-UPDRS II–III–IV scores, axial signs score, SE and 
HY stages, although women had a slightly, but not statistically sig-
nificant, worse HY stage, and more men were demented although 
not statistically significant (Table 1).
Baseline (MeD OFF) Voice and speech 
characteristics
No differences were found between men and women for breath 
support and voice stability at baseline (MED OFF) (Table 2). Voice 
quality differed between men and women at baseline, although 
this difference has been noticed in vocally healthy subjects 
(gender effect) and the values were also similar to vocally healthy 
subjects (25) (Table  2). Values of respiratory breath support 
TaBle 2 | Values for late-stage PD patients are presented as median [IQR, 
25th–75th percentile].
Parkinson’s disease patients 
(N = 24)
normal value
respiratory support for speech
Vowel duration (s) 5.8 [4.4–11.5.8] 22.97 (1.1)b
Voice stability
Pitch break time (s) 1.24 [0.2–2.6.1] NAa
Jitter (%) 0.8 [0.5–1.1] ≤0.5–1%
Voice variability
Sentence F0SD (Hz) 2.4 [1.6–4] 2–4 Hz
Voice quality (hz) Male (N = 14) Female (N = 10) Male Female
F0 125 [104–152] 202 [160–226.8] 128 (36)c 198 (44)c
Values for healthy subjects are presented as mean (SD), as reported in literature 
(25–28).
F0, fundamental frequency; Sentence F0SD, SD of speaking F0 during sentences.
aNot available (healthy voices should have no trouble in maintaining voicing during a 
sustained vowel. Thus is 0% of voice breaks. No standard values are available).
bNormal value for vowel duration is referred to a healthy population aged between 71 
and 80 years old.
cNormal value for voice quality is referred to a healthy population aged between 55 and 
80 years old.
TaBle 3 | Values are presented as median [IQR, 25th–75th percentile].
lsPD patients (N = 24)
MeD OFF MeD On p-Value
MDs-UPDrs-iii 64 [52–77] 50 [40–54] <0.001
Speech 2 [1–3] 2 [1–3] 0.83
Freezing of gait 3 [1–4] 2 [0–3] <0.05 (0.01)
Postural stability 3 [2–4] 3 [2–3] <0.05 (0.014)
Gait 3 [2–4] 3 [2–3] <0.05 (0.01)
Axial signs 10 [7–13] 8 [6–13] <0.05 (0.01)
hY 4 [2–4.75] 4 [2–4] 0.7
maiMs 0 1 [0–6.75] 0.04
Voice respiratory support for speech
Vowel duration (s) 5.8 [4.4–11.5] 7 [3.6–10.6] 0.6
Voice stability
Pitch break time 1.2 [0.2–2.6] 0.8 [0.07–2.5] 0.9
Jitter 0.8 [0.5–1.1] 0.7 [0.4–1] 0.5
Voice quality
F0 154 [123–209] 162 [147–203] 0.2
Voice variability
Sentence F0SD 31 [19–51] 29 [20–40] 0.5
Speech rate 5 [3.6–5.6] 5 [4.2–5.7] 0.2
Statistical significant results are in bold. Axial signs: sum of item 3.1, 3.10–3.12 of the 
MDS-UPDRS-III. p-Value is the results of MED OFF versus MED ON scores.
mAIMS, Modified Abnormal Involuntary Movement Scale; F0, fundamental frequency; 
Sentence F0SD, SD of speaking F0 during sentences; LSPD, late-stage PD; HY, Hoehn 
and Yahr stage.
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(26) and pitch break time (24) of LSPD patients appeared worse 
when compared to the normal values of healthy age-matched 
subjects, stratified for gender (Table 2). Mean jitter values were 
in the normal range (Table 2), although results were borderline 
for men and SD showed a tendency for higher values (27). In 
contrast, F0SD (28) was in the normal range (Table 2). However, 
this result was partially expected as we use a very syntactically 
simple sentence.
A positive moderate correlation was found between disease 
duration and voice quality (R = 0.51; p = 0.013) and a negative 
one with speech rate (R = −0.55; p = 0.008). Motor impairment 
(MDS-UPDRS-III) had a moderate significant correlation with 
respiratory support for speech (R = −0.43; p = 0.045) and pitch 
break time (R = −0.565; p = 0.006). No correlations were found 
between voice and speech features and axial motor impairment, 
neither between speech rate and freezing. When analyzing by 
gender (men and women separately) such correlations were 
partially maintained: (a) voice quality and disease duration: 
men (R = 0.5; p = 0.079) and women (R = 0.36; p = 0.2); (b) 
speech rate and disease duration: men (R = −0.7; p = 0.003) and 
women (R = −0.2; p = 0.5); (c) respiratory support for speech 
and MDS-UPDRS-III: men (R = 0.64; p = 0.017) and women 
(R = −0.7; p = 0.029).
l-Dopa acute challenge Test
No differences between men and women were found when com-
paring motor, voice, and speech variables during both MED OFF 
and MED ON, except for voice quality (F0), as was expected (see 
Table 2 for voice characteristics of healthy subjects). Thus, further 
analyses were carried out by taking into consideration the whole 
LSPD sample and not stratifying by gender.
Motor Response
The median l-dopa dose for the test was 375  mg [IQR: 
277–375]. The median MDS-UPDRS-III score was 64 [IQR: 
52–77] in MED OFF and 50 [IQR: 40–54] in MED ON, with 
a significant median improvement of 20% [IQR: 11.5–32%] 
(p < 0.001) (Table 3). Sub-analysis of MDS-UPDRS-III scores 
for axial signs showed a significant median improvement after 
l-dopa intake for all the subitems, except speech (Table  3). 
3 patients (12.5%) had mild dystonic dyskinesias in MED OFF, 
while 12 (50%) presented slight-moderate choreic dyskinesias 
in MED ON.
Voice and Speech Response
None of voice and speech variables changed significantly after 
l-dopa intake (Table 3).
Equally, separate analysis of non-demented and demented 
patients showed no modification of speech and voice variables 
following l-dopa intake.
DiscUssiOn
The purpose of this study was to explore the l-dopa response of 
speech in the late stage of PD. In order to do this a population of 
LSPD patients underwent an l-dopa challenge while perform-
ing specific vocal tasks during both MED OFF and MED ON 
conditions. No effect of l-dopa was found on speech and voice 
by means of both automated analysis and clinical evaluation, 
although patients had a moderate positive motor response, even 
present for some axial signs, with the exception of speech. Such a 
discrepancy in l-dopa responsiveness between speech and other 
axial signs has been reported only in one previous speech study in 
advanced PD patients (14) and suggests that speech together with 
balance and postural problems could be listed among l-dopa 
resistant axial sign appearing with disease progression.
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Despite not performing a case-controlled study, by comparing 
MED OFF speech and voice characteristics of our patients with 
normative values of the general population we found a severe 
impairment of respiratory support for speech and voice stability, 
as already reported elsewhere (6, 12). We chose to make this com-
parison in the MED OFF condition because it more accurately 
reflects the parkinsonian state of patients. Rigidity associated with 
PD can often lead to disruption of respiratory processes which 
serve to generate air pressure for speech (10). Respiratory support 
for speech may be measured through vowel prolongation, and a 
decrease by an average of fifty percent in vowel prolongation has 
been reported for PD patients when compared to normal healthy 
speakers (10). Among our LSPD patients, vowel prolongation was 
more affected, even in the absence of dyskinesias that can affect 
respiratory control (11). Equally, voice stability, i.e., ability to 
maintain a consistent voice during a stable/sustained vowel with 
laryngeal muscle effort, is impaired in MED OFF, as shown by an 
increase in pitch break time and the tendency for jitter increment. 
Moreover, a tendency for worsening voice quality and speech rate 
was highlighted with disease duration. Voice quality and voice 
variability values in MED OFF were in the normal range although 
the most plausible cause for this finding is methodological, which 
might have resulted in falsely normal values for voice quality 
and variability: we have chosen a declarative sentence for voice 
variability analysis that is syntactically too simple to capture this 
feature; equally, we assessed voice quality using mean F0 instead 
of F0SD which is usually more appropriate but not possible to 
analyze in our patients due to the technical quality of the record-
ings. Interestingly, no correlations were found between speech 
rate and freezing. These data are apparently in contrast with the 
recent findings of Ricciardi and colleagues that showed lower 
scores in the articulation, intelligibility, rate/prosody section of 
the Dysarthria Profile in PD patients with freezing of gait (FOG), 
as assessed by the New FOG questionnaire, if compared to PD 
patients without FOG (29). However, in our study, different 
methodological measures have been adopted in order to assess 
both speech rate and FOG. Moreover, Ricciardi and colleagues 
included younger PD patients, belonging to several HY stages, 
thus a more heterogeneous PD sample, scarcely comparable to 
our LSPD patients.
Our sample of LSPD patients still presented moderately good 
motor response to l-dopa (20% of the MDS-UPDRS-III) when 
compared to our previous report (19), and the frequency of 
dementia was slightly lower (52%) (19). The exclusion of patients 
who could not speak at all or who could not properly understand 
the tasks would have surely created bias. Thus, our sample may 
represent a subset of LSPD patients who present a slightly better 
clinical state compared to other reports (30, 31). Nevertheless, 
even if an influence of dyskinesias on speech performance cannot 
be excluded (11), speech showed no improvement after l-dopa 
intake, whether it was measured clinically or with automated 
analysis that explored the respiratory support for speech (vowel 
duration), voice stability, variability and quality, and speech rate. 
De Letter et  al. evaluated respiratory features among 25 non-
demented PD patients during an l-dopa challenge and reported a 
slight improvement of sustained vowel phonation (11). However, 
due to the clinical differences with our sample, i.e., older patients 
with longer disease duration and worse l-dopa response, these 
results may not be comparable with those published by De Letter 
et  al. Concerning voice stability and variability, if we assume 
that hypokinesia of the voice apparatus is the major pathological 
mechanism of monopitch speech in PD (32, 33), F0SD should 
improve after l-dopa intake and should decline further during 
the disease course. However, data on voice stability/variability 
improvement after l-dopa are inconsistent, and previous reports 
have also failed to show a response of F0SD or jitter to dopamin-
ergic therapy (12, 15, 34). This finding may be related to the usual 
worse response of axial muscles to l-dopa.
A lack of improvement in speech quality (F0) and speech rate 
after l-dopa or apomorphine has already been described in earlier 
PD stages (12, 14, 15, 35). We report similar data in LSPD patients, 
although we have to consider that our patients did not present 
with a severe impairment of voice quality in MED OFF. Thus, an 
improvement would not be expected. A slight improvement of 
speech rate after l-dopa intake has been found in only nine PD 
patients with optimal l-dopa responsiveness and a non-severe 
impairment of speech at baseline, as assessed by the UPDRS-III 
(34). However, Ho et  al. concomitantly reported on a decay of 
rate improvement during the speech testing tasks (34). Thus, it is 
likely that improvement in speech rate is not maintained during 
the tasks.
Several factors can contribute to the lack of speech and voice 
responsiveness to l-dopa in PD patients, especially in the late 
disease stage.
Speech production is essentially a series of skilled motor 
gestures that require upstream central coordination mediated 
by cerebral networks for speech production. Indeed, the globus 
pallidus (GP) produces a phasic burst of activity that triggers the 
supplementary motor area neural discharge, allowing cortical 
motor set for movement preparation and subsequent execution 
(34). In PD, the impairment of GP activity alters those mecha-
nisms, resulting in diminished movement amplitude and impair-
ment of movement sequencing. Such a process affects speech 
production as well as body movement, and a correlation between 
speech hypophonia/speech intensity and severity of body brad-
ykinesia has been suggested (34). l-Dopa has been shown to 
have an effect on preparatory motor set, resulting in hypokinesia 
improvement, but failed to affect movement sequencing (36). 
Likewise, concerning speech, while still controversial, a few stud-
ies have reported on a slight l-dopa positive effect on loudness 
(speech intensity), intonation (speech variability), and speech 
rate (12, 34) at least in early-advanced PD stages. Conversely, 
speech stability and variability seem to be definitively impervi-
ous to dopaminergic therapy (9, 12). Interestingly, and contrary 
to previous suggestions, we did not find neither an improvement 
of speech intensity or rate with l-dopa nor a correlation between 
speech and voice severity and motor symptoms that still respond 
to l-dopa, namely, bradykinesia and rigidity. These findings may 
support a non-dopaminergic involvement in speech neurocir-
cuitry as already supposed in earlier disease stages (35), and 
this is even more likely in LSPD (37). Alternatively, a higher 
dose of l-dopa could be needed to improve speech, as is often 
the case with gait dysfunction. The usual absence of significant 
rigidity in late-stage patients (19, 31) may also have contributed 
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to the lack of correlation between speech intensity and motor 
impairment. Furthermore, we have to consider that a loss of 
striatal responsiveness is related to disease progression and is 
likely responsible for a decrease or loss of clinical response to 
dopaminergic therapy of several motor symptoms (19), which 
also probably affects speech responsiveness. Finally, motor 
speech production also depends on the appropriate function of 
peripheral nervous system (7). Dysfunction of speech articula-
tion may also be partly attributed to muscular denervation and 
atrophy, resulting in respiratory muscles impairment whose 
function does not improve with l-dopa as recently shown in a 
sample of PD patients in HY 2–4 (38). Such muscle impairment 
is presumably even more severe among older PD patients who 
have a worse motor status as our sample.
Our findings highlight the need for alternative non-dopamin-
ergic/non-pharmacologic treatments to improve communication 
of LSPD patients. For instance, the Lee Silverman Voice Treatment 
has shown some efficacy in the treatment of voice and speech 
problems of PD patients (7). However, its applicability to LSPD 
patients should be verified due to the level of collaboration that it 
requires and the degree of disability of those patients.
study limitations
Some limitations of our study must be highlighted. Due to the 
clinical disability of LSPD patients, recordings were performed in 
a home environment and not in a laboratory setting. This implied 
accepting samples varying in context, over different time periods, 
and recorded in non-standard environments. Nevertheless, the 
quality and reliability of the recordings were evaluated by a 
speech language therapist. Patients’ disabilities can also have 
influenced choice of tasks. For instance, we selected a simple task 
for voice variability assessment, which was probably not sensitive 
enough to detect l-dopa effect in voice/intonation variability, or 
voice variability defect at baseline. Finally, clinical assessment 
of patients was not blinded. However, there was concordance 
between clinical and automated assessments of speech.
conclusion
To the best of our knowledge, this is the first report on l-dopa 
response of speech and voice in a sample of LSPD patients by 
means of both a clinical rating scale and automated analysis. 
Speech is severely affected among LSPD patients, as already 
reported for PD patients in earlier disease stages (1, 4).
Although l-dopa still had some effect on motor performance, 
including some axial signs, we found no improvement in speech 
and voice. Clinical management and research should consider the 
applicability of non-pharmacological treatments for speech and 
voice impairment among LSPD patients.
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